Xalost S is developed by Taejoon Pharmaceutical Co., Ltd..

What development phase is Xalost S in?

Xalost S is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Xalost S

Taejoon Pharmaceutical Co., Ltd. · FDA-approved active Small molecule Quality 2/100

Xalost S, marketed by Taejoon Pharmaceutical Co., Ltd., is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Xalost S
Sponsor	Taejoon Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Xalost S CI brief — competitive landscape report
Xalost S updates RSS · CI watch RSS
Taejoon Pharmaceutical Co., Ltd. portfolio CI